Clinical Significance of CD161+CD4+ T Cells in the Development of Chronic Antibody-mediated Rejection in Kidney Transplant Recipients

Overview

Journal PLoS One

Specialties General Medicine
Science

Date 2018 Jul 17

PMID 30011312

Citations 5

Authors

Kyoung Woon Kim

Bo-Mi Kim

Kyoung Chan Doh

Chan-Duck Kim

Kyung Hwan Jeong

Sang-Ho Lee

Chul Woo Yang

Byung Ha Chung

Affiliations

Soon will be listed here.

Abstract

In this study, we investigated whether CD161+CD4+ T cells can reflect the Th17 pathway in kidney transplant recipients (KTRs) and investigated the clinical significance of this cell type in chronic antibody-mediated rejection (cAMR) in KT. First, we investigated the relationship between CD161+CD4+ T and Th17 cells by flow cytometry and microarray analysis in an in vitro study. Second, we compared the proportion of T cell subsets including CD161+CD4+ T cells in cAMR (n = 18), long-term graft survival (LTGS) (n = 46), and interstitial fibrosis/tubular atrophy (IF/TA) (n = 22). We compared CD161+ cell infiltration between cAMR and IF/TA and also examined the effect of CD161+ T cells on human renal proximal tubular epithelial cells (HRPTEpiC). In flow cytometry, the proportion of CD161+CD4+ T cells showed a significant correlation with the proportion of Th17 cells. In microarray analysis, transcripts associated with the Th17 pathway such as IL18RAP, IL-18R1, IL23R, IL12RB2, RORC, TBX21, and EOMES were upregulated in CD161+ cells compared with CD161- cells. In an ex vivo study, only CD161+CD4+ T cells showed a significant increase in the cAMR group compared with IF/TA and LTGS groups. In allograft tissue, CD161+ cells showed a higher level of infiltration in the cAMR group than the IF/TA group. Lastly, CD161+ T cells increased the production of inflammatory cytokines from HRPTEpiC in a dose-dependent manner. This study suggests that monitoring of CD161+ T cells can be useful to detect the progression of cAMR.

Citing Articles

Combined Use of Tocilizumab and Mesenchymal Stem Cells Attenuate the Development of an Anti-HLA-A2.1 Antibody in a Highly Sensitized Mouse Model.

Fang X, Cui S, Lee H, Min J, Lim S, Oh E Int J Mol Sci. 2024; 25(3).

PMID: 38338657 PMC: 10855827. DOI: 10.3390/ijms25031378.

Single-Cell Profiling of Kidney Transplant Recipients With Immunosuppressive Treatment Reveals the Dynamic Immune Characteristics.

Liu Y, Liu X, Zhou S, Xu R, Hu J, Liao G Front Immunol. 2021; 12:639942.

PMID: 33959124 PMC: 8093626. DOI: 10.3389/fimmu.2021.639942.

BAFF Inhibition Effectively Suppresses the Development of Anti-HLA.A2 Antibody in the Highly Sensitized Mouse Model.

Min J, Shin Y, Lee H, Kim B, Park K, Doh K Int J Mol Sci. 2021; 22(2).

PMID: 33467096 PMC: 7830620. DOI: 10.3390/ijms22020861.

Immune cell repertoires in breast cancer patients after adjuvant chemotherapy.

Gustafson C, Jadhav R, Cao W, Qi Q, Pegram M, Tian L JCI Insight. 2020; 5(4).

PMID: 32102986 PMC: 7101137. DOI: 10.1172/jci.insight.134569.

The TreaT-Assay: A Novel Urine-Derived Donor Kidney Cell-Based Assay for Prediction of Kidney Transplantation Outcome.

Thieme C, Weist B, Mueskes A, Roch T, Stervbo U, Rosiewicz K Sci Rep. 2019; 9(1):19037.

PMID: 31836826 PMC: 6911059. DOI: 10.1038/s41598-019-55442-x.

References

Haas M, Sis B, Racusen L, Solez K, Glotz D, Colvin R . Banff 2013 meeting report: inclusion of c4d-negative antibody-mediated rejection and antibody-associated arterial lesions. Am J Transplant. 2014; 14(2):272-83. DOI: 10.1111/ajt.12590. View

Gupta S, Bi R, Su K, Yel L, Chiplunkar S, Gollapudi S . Characterization of naïve, memory and effector CD8+ T cells: effect of age. Exp Gerontol. 2004; 39(4):545-50. DOI: 10.1016/j.exger.2003.08.013. View

LeBleu V, Taduri G, OConnell J, Teng Y, Cooke V, Woda C . Origin and function of myofibroblasts in kidney fibrosis. Nat Med. 2013; 19(8):1047-53. PMC: 4067127. DOI: 10.1038/nm.3218. View

Fergusson J, Smith K, Fleming V, Rajoriya N, Newell E, Simmons R . CD161 defines a transcriptional and functional phenotype across distinct human T cell lineages. Cell Rep. 2014; 9(3):1075-88. PMC: 4250839. DOI: 10.1016/j.celrep.2014.09.045. View

Chung B, Oh H, Piao S, Sun I, Kang S, Choi S . Higher infiltration by Th17 cells compared with regulatory T cells is associated with severe acute T-cell-mediated graft rejection. Exp Mol Med. 2011; 43(11):630-7. PMC: 3249589. DOI: 10.3858/emm.2011.43.11.071. View

Loong C, Lin C, Lui W . Expression of interleukin-17 as a predictive parameter in acute renal allograft rejection. Transplant Proc. 2000; 32(7):1773. DOI: 10.1016/s0041-1345(00)01382-8. View

. KDIGO clinical practice guideline for the care of kidney transplant recipients. Am J Transplant. 2009; 9 Suppl 3:S1-155. DOI: 10.1111/j.1600-6143.2009.02834.x. View

Mitchell P, Afzali B, Lombardi G, Lechler R . The T helper 17-regulatory T cell axis in transplant rejection and tolerance. Curr Opin Organ Transplant. 2009; 14(4):326-31. DOI: 10.1097/MOT.0b013e32832ce88e. View

Annunziato F, Cosmi L, Liotta F, Maggi E, Romagnani S . Defining the human T helper 17 cell phenotype. Trends Immunol. 2012; 33(10):505-12. DOI: 10.1016/j.it.2012.05.004. View

10.

Crispim J, Grespan R, Martelli-Palomino G, Rassi D, Costa R, Saber L . Interleukin-17 and kidney allograft outcome. Transplant Proc. 2009; 41(5):1562-4. DOI: 10.1016/j.transproceed.2009.01.092. View

11.

Mukasa R, Balasubramani A, Lee Y, Whitley S, Weaver B, Shibata Y . Epigenetic instability of cytokine and transcription factor gene loci underlies plasticity of the T helper 17 cell lineage. Immunity. 2010; 32(5):616-27. PMC: 3129685. DOI: 10.1016/j.immuni.2010.04.016. View

12.

Maluf D, Dumur C, Suh J, Lee J, Cathro E, King A . Evaluation of molecular profiles in calcineurin inhibitor toxicity post-kidney transplant: input to chronic allograft dysfunction. Am J Transplant. 2014; 14(5):1152-1163. PMC: 4377109. DOI: 10.1111/ajt.12696. View

13.

Yang Y, Xu J, Niu Y, Bromberg J, Ding Y . T-bet and eomesodermin play critical roles in directing T cell differentiation to Th1 versus Th17. J Immunol. 2008; 181(12):8700-10. PMC: 2834216. DOI: 10.4049/jimmunol.181.12.8700. View

14.

Seo J, Moon H, Kim S, Moon J, Jeong K, Lee Y . Both absolute and relative quantification of urinary mRNA are useful for non-invasive diagnosis of acute kidney allograft rejection. PLoS One. 2017; 12(6):e0180045. PMC: 5487057. DOI: 10.1371/journal.pone.0180045. View

15.

San Segundo D, Lopez-Hoyos M, Fernandez-Fresnedo G, Benito M, Ruiz J, Benito A . T(H)17 versus Treg cells in renal transplant candidates: effect of a previous transplant. Transplant Proc. 2008; 40(9):2885-8. DOI: 10.1016/j.transproceed.2008.09.043. View

16.

Cosmi L, De Palma R, Santarlasci V, Maggi L, Capone M, Frosali F . Human interleukin 17-producing cells originate from a CD161+CD4+ T cell precursor. J Exp Med. 2008; 205(8):1903-16. PMC: 2525581. DOI: 10.1084/jem.20080397. View

17.

Chung B, Kim K, Kim B, Doh K, Cho M, Yang C . Increase of Th17 Cell Phenotype in Kidney Transplant Recipients with Chronic Allograft Dysfunction. PLoS One. 2015; 10(12):e0145258. PMC: 4696852. DOI: 10.1371/journal.pone.0145258. View

18.

Chung B, Kim K, Sun I, Choi S, Park H, Jeon E . Increased interleukin-17 producing effector memory T cells in the end-stage renal disease patients. Immunol Lett. 2011; 141(2):181-9. DOI: 10.1016/j.imlet.2011.10.002. View

19.

Chung B, Oh H, Piao S, Hwang H, Sun I, Choi S . Clinical significance of the ratio between FOXP3 positive regulatory T cell and interleukin-17 secreting cell in renal allograft biopsies with acute T-cell-mediated rejection. Immunology. 2012; 136(3):344-51. PMC: 3385034. DOI: 10.1111/j.1365-2567.2012.03588.x. View

20.

Gore-Hyer E, Shegogue D, Markiewicz M, Lo S, Hazen-Martin D, Greene E . TGF-beta and CTGF have overlapping and distinct fibrogenic effects on human renal cells. Am J Physiol Renal Physiol. 2002; 283(4):F707-16. DOI: 10.1152/ajprenal.00007.2002. View